Literature DB >> 18353934

Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease.

Nawfal R Hussein1, Marjan Mohammadi, Yeganeh Talebkhan, Masoumeh Doraghi, Darren P Letley, Merdan K Muhammad, Richard H Argent, John C Atherton.   

Abstract

Helicobacter pylori causes peptic ulceration and gastric adenocarcinoma; the latter is common in Iran but not in Iraq. We hypothesized that more virulent H. pylori strains may be found in Iran than in Iraq and so compared established and newly described virulence factors in strains from these countries. We studied 59 unselected dyspeptic patients from Iran and 49 from Iraq. cagA was found in similar proportions of strains from both countries (76% in Iran versus 71% in Iraq) and was significantly associated with peptic ulcer disease in Iraq (P <or= 0.01) but not in Iran. cagA alleles encoding four or more tyrosine phosphorylation motifs were found in 12% of the Iranian strains but none of the Iraqi strains (P = 0.02). There were no significant differences in the vacA signal-, middle-, or intermediate-region types between Iranian and Iraqi strains. Among the strains from Iran, vacA genotypes showed no specific peptic ulcer associations, but among the strains from Iraq, vacA i1 strains were associated with gastric ulcer (P <or= 0.02), mimicking their previously demonstrated association with gastric cancer in Iran. dupA was found in similar proportions of Iranian and Iraqi strains (38% and 32%, respectively) and was associated with peptic ulceration in Iraqi patients (P <or= 0.01) but not Iranian patients. H. pylori strains from Iraq and Iran possess virulence factors similar to those in Western countries. The presence of cagA with more phosphorylation motifs in Iranian strains may contribute to the higher incidence of gastric cancer. However, the association between strain virulence markers and disease in Iraq but not Iran suggests that other host and environmental factors may be more important in the disease-prone Iranian population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353934      PMCID: PMC2395113          DOI: 10.1128/JCM.01737-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  VacA from Helicobacter pylori: a hexameric chloride channel.

Authors:  H Iwamoto; D M Czajkowsky; T L Cover; G Szabo; Z Shao
Journal:  FEBS Lett       Date:  1999-04-30       Impact factor: 4.124

2.  Simple method for determination of the number of Helicobacter pylori CagA variable-region EPIYA tyrosine phosphorylation motifs by PCR.

Authors:  Richard H Argent; Youli Zhang; John C Atherton
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Comparison of cancer incidence in Iran and Iranian immigrants to British Columbia, Canada.

Authors:  Parvin Yavari; T Gregory Hislop; Chris Bajdik; Alireza Sadjadi; Mehdi Nouraie; Masoud Babai; Reza Malekzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2006 Jan-Mar

4.  Differences in genotypes of Helicobacter pylori from different human populations.

Authors:  D Kersulyte; A K Mukhopadhyay; B Velapatiño; W Su; Z Pan; C Garcia; V Hernandez; Y Valdez; R S Mistry; R H Gilman; Y Yuan; H Gao; T Alarcón; M López-Brea; G Balakrish Nair; A Chowdhury; S Datta; M Shirai; T Nakazawa; R Ally; I Segal; B C Wong; S K Lam; F O Olfat; T Borén; L Engstrand; O Torres; R Schneider; J E Thomas; S Czinn; D E Berg
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

5.  Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo.

Authors:  Matthias Selbach; Stefan Moese; Christof R Hauck; Thomas F Meyer; Steffen Backert
Journal:  J Biol Chem       Date:  2002-01-11       Impact factor: 5.157

6.  The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease.

Authors:  N L Arents; A A van Zwet; J C Thijs; A M Kooistra-Smid; K R van Slochteren; J E Degener; J H Kleibeuker; L J van Doorn
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

7.  Duodenal ulcer promoting gene of Helicobacter pylori.

Authors:  Hong Lu; Ping-I Hsu; David Y Graham; Yoshio Yamaoka
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

8.  A 12-amino-acid segment, present in type s2 but not type s1 Helicobacter pylori VacA proteins, abolishes cytotoxin activity and alters membrane channel formation.

Authors:  M S McClain; P Cao; H Iwamoto; A D Vinion-Dubiel; G Szabo; Z Shao; T L Cover
Journal:  J Bacteriol       Date:  2001-11       Impact factor: 3.490

9.  Cancer occurrence in Iran in 2002, an international perspective.

Authors:  Alireza Sadjadi; Mehdi Nouraie; Mohammad Ali Mohagheghi; Alireza Mousavi-Jarrahi; Reza Malekezadeh; Donald Maxwell Parkin
Journal:  Asian Pac J Cancer Prev       Date:  2005 Jul-Sep

Review 10.  The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases.

Authors:  John C Atherton
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

View more
  57 in total

1.  cagA and vacA status and influence of Helicobacter pylori infection on serum oxidative DNA damage in Iranian patients with peptic ulcer disease.

Authors:  Z Khodaii; S M H Ghaderian; R Akbarzadeh Najar; H Nejati; A S Tabatabaei Panah
Journal:  Ir J Med Sci       Date:  2010-08-20       Impact factor: 1.568

2.  Clinical relevance of cagL gene and virulence genotypes with disease outcomes in a Helicobacter pylori infected population from Iran.

Authors:  Abbas Yadegar; Ashraf Mohabati Mobarez; Masoud Alebouyeh; Tabassom Mirzaei; Terry Kwok; Mohammad Reza Zali
Journal:  World J Microbiol Biotechnol       Date:  2014-05-23       Impact factor: 3.312

3.  Prevalence and genotypes of Helicobacter pylori in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova Region of Turkey.

Authors:  Togrul Nagiyev; Erkan Yula; Bahri Abayli; Fatih Koksal
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

4.  Helicobacter pylori homB, but not cagA, is associated with gastric cancer in Iran.

Authors:  Amin Talebi Bezmin Abadi; Alireza Rafiei; Abolghasem Ajami; Vahid Hosseini; Tarang Taghvaei; Kathleen R Jones; D Scott Merrell
Journal:  J Clin Microbiol       Date:  2011-07-06       Impact factor: 5.948

5.  dupA1 is associated with duodenal ulcer and high interleukin-8 secretion from the gastric mucosa.

Authors:  Nawfal R Hussein; Shahlaa M Abdullah; Azad M Salih; Mahde A Assafi
Journal:  Infect Immun       Date:  2012-08       Impact factor: 3.441

6.  A novel method for genotyping the Helicobacter pylori vacA intermediate region directly in gastric biopsy specimens.

Authors:  Rui M Ferreira; Jose C Machado; Darren Letley; John C Atherton; Maria L Pardo; Carlos A Gonzalez; Fatima Carneiro; Ceu Figueiredo
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 7.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

8.  A study of Helicobacter pylori-associated gastritis patterns in Iraq and their association with strain virulence.

Authors:  Nawfal R Hussein; Sarbar M Napaki; John C Atherton
Journal:  Saudi J Gastroenterol       Date:  2009-04       Impact factor: 2.485

9.  Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes.

Authors:  Seiji Shiota; Osamu Matsunari; Masahide Watada; Katsuhiro Hanada; Yoshio Yamaoka
Journal:  Gut Pathog       Date:  2010-10-31       Impact factor: 4.181

10.  Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan.

Authors:  Javed Yakoob; Shahab Abid; Zaigham Abbas; Wasim Jafri; Zubair Ahmad; Rashida Ahmed; Muhammad Islam
Journal:  BMC Gastroenterol       Date:  2009-11-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.